Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
Rebecca Gardner(Center for Infectious Disease Research), Michael C. Jensen(Seattle Children's Hospital)
Cited by 284
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754